Cabotegravir sodium - Generic Drug Details

What are the generic sources for cabotegravir sodium and what is the scope of freedom to operate?

Cabotegravir sodium is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cabotegravir sodium has one hundred and twenty-six patent family members in thirty-three countries.

One supplier is listed for this compound.

Summary for cabotegravir sodium

International Patents:	126
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	1
What excipients (inactive ingredients) are in cabotegravir sodium?	cabotegravir sodium excipients list
DailyMed Link:	cabotegravir sodium at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for cabotegravir sodium

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for cabotegravir sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ViiV Healthcare	Phase 1

See all cabotegravir sodium clinical trials

Pharmacology for cabotegravir sodium

Drug Class	Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Mechanism of Action	HIV Integrase Inhibitors Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for cabotegravir sodium

J05AJ	Integrase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for cabotegravir sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes			Y	Y
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes			Y	Y
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes

International Patents for cabotegravir sodium

Country	Patent Number	Title	Estimated Expiration
Slovenia	1874117
European Patent Office	3187225	DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
South Korea	20080009733	POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Ukraine	96568	ПОЛІЦИКЛІЧНЕ ПОХІДНЕ КАРБАМОЇЛПІРИДОНУ ЯК ІНГІБОР ВІЛ-ІНТЕГРАЗИ[ПОЛИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ КАРБАМОИЛПИРИДОНА КАК ИНГИБИТОР ВИЧ-ИНТЕГРАЗЫ (POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE AS HIV-INTEGRASE INHIBITOR)
Portugal	3284520

Supplementary Protection Certificates for cabotegravir sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	14C0041	France		PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
2465580	CA 2021 00010	Denmark		PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221
2465580	C20210013 00397	Estonia		PRODUCT NAME: KABOTEGRAVIIR;REG NO/DATE: EU/1/120/1481; 21.12.2020
1874117	CA 2014 00032	Denmark		PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
2465580	C02465580/01	Switzerland		PRODUCT NAME: CABOTEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67740 08.10.2021

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: CABOTEGRAVIR SODIUM

Last updated: July 28, 2025

---

Introduction

Cabotegravir sodium, a long-acting integrase inhibitor, has rapidly garnered attention within the pharmaceutical landscape due to its innovative approach to HIV treatment and prevention. As the first injectable, long-acting antiretroviral therapy (ART), cabotegravir offers promising opportunities for expanding HIV management, affecting market dynamics profoundly. This article explores the evolving market landscape, key drivers, challenges, and financial trajectories shaping the future of cabotegravir sodium.

---

Market Overview

Cabotegravir sodium was initially developed by ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK) and Pfizer, targeting HIV management with a focus on improving patient adherence through injectable formulations. Its key product, Apretude (intramuscular injection), received FDA approval in 2021 for the prevention of HIV in high-risk populations, marking its pivotal role in HIV prophylaxis. Subsequently, its application extended to HIV treatment, notably in combination with rilpivirine as Cabenuva, an injectable therapy approved by the FDA in 2021 for treating adults with HIV-1.

The global HIV therapeutics market was valued at approximately USD 29 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) exceeding 5% over the next five years, driven by unmet medical needs, aging populations, and expanding awareness of HIV prevention strategies[1]. Within this segment, long-acting treatments like cabotegravir are poised to capture significant market share, especially among populations with adherence challenges to daily oral regimens.

---

Market Drivers

1. Unmet Clinical Needs & Adherence Enhancement

One of cabotegravir's primary market drivers is its potential to improve adherence. Daily oral regimens often lead to missed doses and treatment failure. The injectable, long-acting formulation reduces the pill burden, encouraging consistent treatment and pre-exposure prophylaxis (PrEP) adherence. Clinical trials demonstrated superior adherence with cabotegravir injections compared to daily oral regimens, translating to better viral suppression and prevention rates[2].

2. Regulatory Approvals and Expanding Indications

Regulatory agencies worldwide have approved cabotegravir for distinct indications, facilitating its market penetration. The FDA’s approval of Apretude for PrEP and Cabenuva for HIV treatment marks significant milestones. Expected approval pathways in Europe, Asia, and Latin America will further broaden its use globally, especially in resource-limited settings where adherence issues are prevalent.

3. Competitive Edge and Innovation

Cabotegravir offers a competitive edge over traditional oral therapies due to its dosing schedule—administration every one or two months—in comparison to daily pills. This innovation not only improves patient quality of life but also positions it favorably against existing drugs like dolutegravir or rilpivirine.

4. Growing HIV Incidence and Prevention Focus

Despite advances, new HIV infections still occur globally, with around 1.5 million new cases reported annually[3]. Governments and international organizations emphasize prevention strategies, adopting long-acting injectables like cabotegravir to reduce transmission, particularly among high-risk groups such as men who have sex with men (MSM) and transgender populations.

Market Challenges

1. High Cost and Reimbursement Obstacles

Price points for cabotegravir-based therapies are significantly higher than oral alternatives, potentially limiting access, especially in lower-income countries. Limited reimbursement pathways and price negotiations may inhibit widespread adoption, restricting market growth.

2. Infrastructure and Healthcare Delivery

Administering long-acting injectables necessitates healthcare infrastructure, trained personnel, and cold-chain logistics. This requirement poses challenges in resource-constrained settings, impacting global reach.

3. Competition and Emerging Therapies

The market for HIV management remains competitive, with intramural developments of other long-acting agents and digital adherence tools. Companies like Merck, GSK, and others are exploring alternative formulations and delivery systems, which could challenge cabotegravir's market dominance.

4. Long-Term Safety and Resistance Concerns

Long-term safety profiles and resistance development are critical for sustained adoption. Ongoing studies are essential to demonstrate durability and safety, particularly for preventive indications, where treatment costs might be sustained over decades.

---

Financial Trajectory and Market Potential

Revenue Forecasts and Growth Opportunities

The initial success of cabotegravir formulations can be gauged through sales of Cabenuva, which generated USD 27 million in its debut quarter post-approval[4]. Analysts project the global HIV long-acting injectable market will reach USD 5 billion by 2027, with cabotegravir capturing approximately 50% of this niche segment, supported by escalated use in PrEP and HIV treatment.

Pricing Strategies and Market Penetration

In high-income markets, the pricing of cabotegravir remains competitive due to the benefit of superior adherence and clinical outcomes. Pricing strategies may involve tiered models and partnerships with government and non-governmental organizations to enhance affordability.

R&D and Pipeline Development

Continued R&D investment could extend cabotegravir's utility. Emerging formulations—such as implants or alternative administration routes—could diversify revenue streams if successful. Additionally, expansion into pediatric populations and co-morbidities will broaden its commercial scope.

Geographical Expansion and Market Penetration

Major markets like North America and Europe are leading in adoption. However, significant growth opportunities exist in Asia-Pacific and Africa, driven by increasing HIV prevalence, government support, and declining drug prices through generic manufacturing collaborations.

---

Strategic Considerations for Stakeholders

• Pharmaceutical Companies: Focus on expanding indication spectrum, optimizing pricing, and ensuring supply chain robustness.
• Healthcare Providers: Emphasize patient education on injection protocols and long-term adherence benefits.
• Regulators: Facilitate accelerated approvals and reimbursement schemes to enhance accessibility.
• Investors: Monitor clinical pipeline progress, regulatory milestones, and market expansion strategies for valuation insights.

---

Conclusion

Cabotegravir sodium represents a transformative advancement in HIV therapeutics and prophylaxis, with distinctive market dynamics driven by its innovative delivery mechanism and addressing unmet needs. While high costs and logistical challenges hinder mass adoption, strategic investments, expanded indications, and global health initiatives can unlock substantial revenue potential. Its trajectory reflects broader shifts toward long-acting, patient-centric treatments, promising a significant stake in the future HIV management market.

---

Key Takeaways

• Market Potential: The global HIV long-acting injectable market, led by cabotegravir, is projected to grow rapidly, reaching USD 5 billion by 2027.
• Driver Factors: Enhanced adherence, regulatory approvals, and increasing prevention efforts underpin robust growth prospects.
• Challenges: High costs, infrastructure needs, and resistance concerns threaten market penetration, especially in low-income regions.
• Financial Outlook: Early sales show promising trends, with significant upside fueled by expanded indications and geographies.
• Strategic Focus: Stakeholders should prioritize affordability, infrastructure development, and pipeline innovation to sustain growth.

---

FAQs

1. What makes cabotegravir sodium unique among HIV treatments?
Cabotegravir's long-acting injectable formulation reduces dosing frequency to once every one or two months, improving adherence and patient convenience over daily oral regimens.

2. How does cabotegravir impact HIV prevention strategies?
As an approved PrEP option (Apretude), cabotegravir provides an effective alternative to daily oral PrEP, especially beneficial for populations with adherence challenges.

3. What are the main barriers to widespread adoption of cabotegravir?
High treatment costs, logistical challenges in administration, infrastructure requirements, and resistance concerns are primary barriers.

4. Which regions are expected to see the most growth in cabotegravir usage?
North America and Europe currently lead adoption; however, Asia-Pacific and Africa present significant future market opportunities.

5. What is the future outlook for cabotegravir in HIV management?
With ongoing clinical trials, pipeline developments, and expanding indications, cabotegravir is poised to play a central role in comprehensive HIV prevention and treatment strategies globally.

---

Sources:

1. Statista. Global HIV therapeutics market size, 2021.
2. Swindells, S., et al. (2021). "Long-acting injectable cabotegravir for HIV prevention." NEJM.
3. UNAIDS. Global HIV & AIDS statistics — 2021.
4. GSK. Cabenuva sales report, Q2 2022.